Skip to main content
PMC home page
Annals of Oncology logoLink to Annals of Oncology
. 2019 Aug 20;30(12):2013–2014. doi: 10.1093/annonc/mdz237

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P G Corrie, A Marshall, P D Nathan, P Lorigan, M Gore, S Tahir, G Faust, C G Kelly, M Marples, S J Danson, E Marshall, S J Houston, R E Board, A M Waterston, J P Nobes, M Harries, S Kumar, A Goodman, A Dalgleish, A Martin-Clavijo, S Westwell, R Casasola, D Chao, A Maraveyas, P M Patel, C H Ottensmeier, D Farrugia, A Humphreys, B Eccles, G Young, E O Barker, C Harman, M Weiss, K A Myers, A Chhabra, S H Rodwell, J A Dunn, M R Middleton, on behalf of the AVAST-M Investigators
PMCID: PMC6938599  PMID: 31430371

Ann Oncol 2018; 29(8): 1843–1852 (doi: 10.1093/annonc/mdy229)

In the original article, there was an error in Figure 3. The figure has now been corrected as below in the online version of the article.

Figure 3.

Figure 3.

Open in a new tab

Articles from Annals of Oncology are provided here courtesy of Oxford University Press

RESOURCES